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Our study presented the benefit of CYP2C9-status guided valproate therapy over 
symptom-driven therapy in children by more precise dosing and by minimizing the risk of 
side effects, such as increased alkaline phosphatase and hyperammonemia. CYP2C9 
genotyping for loss-of-function mutations can identify patients with permanent poor valproate 
metabolism; however, inferring the rate of valproate metabolism merely from CYP2C9 
genotype can lead to false prediction. Due to phenoconversion, patients carrying wild 
CYP2C9*1/*1 genotype can be switched into transient poor metabolism which can influence 
the manifestation of valproate side effects.1 Downregulation of CYP2C9 expression was 
observed in epileptic patients due to the seizure-induced cytokine release which represses 
nuclear receptors involved in CYP2C9 expression.2 Therefore, the ratio of poor CYP2C9 
metabolizers is higher than it is predicted from CYP2C9 genotype. The ratio of low CYP2C9 
expresser children in the control and CYPtest groups was still assumed to be similar, since the 
patients enrolled in this study were all newly diagnosed with epilepsy and were on valproate 
monotherapy. Thus, misdosing was considered to contribute to the higher ratio of control 
patients out of the valproate therapeutic range. Toth et al (2015)2 have reported that the 
pediatric patients with various CYP2C9-status required different valproate dosing for 
therapeutic serum concentrations: target valproate dose of 30-40 mg/kg for normal CYP2C9 
expressers with CYP2C9*1/*1 genotype, whereas reduced dose for low expressers and 
patients carrying loss-of-function mutations. In CYPtest group, we applied the dose of 
36.1±6.8 mg/kg for normal expressers carrying CYP2C9*1/*1, 17.5±5.7 mg/kg for low 
expressers and for children with loss-of-function mutations, whereas the dose of 25.0±15.8 
mg/kg was applied for control patients. 
CYP2C9-status controlled valproate therapy was demonstrated to reduce 
hyperammonemia in CYPtest children (1/51 in CYPtest group vs 8/47 in control group). The 
prevalence of hyperammonemia in the control group (17%) was similar to those (15.5%) 
reported in pediatric patients under valproate monotherapy by Yamamoto (2013)3. The 
elevation of serum ammonia levels always accompanied with increased alkaline phosphatase 
and with valproate concentrations higher than 100 µg/ml. Moreover, the children with 
hyperammonemia both in the control and in CYPtest groups displayed one or some of the 
secondary symptomes, such as somnolence, fatigue, consciousness or behavior disturbances. 
Valproate-induced hyperammonemia, which is associated with impaired urea cycle, can occur 
with normal serum aminotransferase and bilirubin levels. Yamamoto (2012)4 and Tseng 
(2014)5 reported significant correlation between blood ammonia levels and valproate dosage; 
thus, they suggested to assay ammonia levels, primarily in patients with secondary symptoms. 
Although fatal outcome as a consequence of valproate therapy is relatively rare, it is 
more frequent in pediatric patients, especially in children younger than 2 years of age (1/500), 
than in adults. On the other hand, the prevalence of hyperammonemia is considered to be high 
under valproate therapy comparing to non-valproate antiepileptic therapy.3 We think that the 
early knowledge of patients’ CYP2C9-status and the CYP2C9-status guided treatment can 
significantly prevent valproate misdosing and the risk of hyperammonemia in children; thus, 
it can improve the safety of antiepileptic therapy. 
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